Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.23.2
Licensing and Other Arrangements - Janssen Biotech (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2023
USD ($)
Aug. 31, 2019
USD ($)
Jun. 30, 2023
USD ($)
item
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2022
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers     $ 1,125 $ 525 $ 1,125 $ 3,275    
Janssen Biotech Inc. | License Agreement                
Licensing and other arrangements                
Cash payment received   $ 2,500            
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events   $ 3,000            
Percentage of royalty on worldwide net sales of each product upon commercialization   0.75%            
Number of milestones earned during the period | item     3          
Revenue from contracts with customers     $ 1,100 $ 0 1,100 $ 0 $ 2,500  
Contract assets     0   0     $ 0
Contract liabilities     0   0     0
Capitalized contract costs     0   $ 0     $ 0
Janssen Biotech Inc. | License Agreement | Dosing of first patient in a Phase 3 clinical trial                
Licensing and other arrangements                
Revenue from contracts with customers $ 500              
Janssen Biotech Inc. | License Agreement | Milestone achieved pursuant to agreement                
Licensing and other arrangements                
Revenue from contracts with customers     $ 600